Skip to main content
Premium Trial:

Request an Annual Quote

John Kolman, Claire Fraser-Ligget, Steven St. Peter

Premium
BioReliance has tapped John Kolman to take over as senior director of research and development. Kolman formerly worked at Invitrogen as principal scientist on the HLA Single Antigen Initiative and lung cancer biomarker programs. He also studied DNA replication initiation at the Salk Institute.
 

 
Claire Fraser-Ligget and Steven St. Peter will not stand for re-election as directors of Helicos Biosciences at the company’s upcoming May stockholder’s meeting, according to a filing with the US Securities and Exchange Commission
 
Until the annual meeting, St. Peter will continue as a member of the Nominating and Corporate Governance Committee and Fraser-Liggett will continue to serve as a member of the Compensation Committee
 
Helicos said that neither of the individuals made their decision due to any disagreement with the company.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.